This work demonstrates a proof-of-conceptfor antigen-specific targeting of polymersome nanomedicines, targeteddelivery of a stapled peptide in vivo, and synergisticdual intrinsic apoptotic therapy against DLBCL via direct p53 reactivationand BCL-2 family modulation. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.